There are 2934 resources available
4511 - POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Pascal Hammel
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4623 - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Presenter: Philippe Merle
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3561 - Comprehensive Genomic Profiling (CGP) of mixed hepatocellular cholangiocarcinomas (cHCC-CCA)
Presenter: Karthikeyan Murugesan
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
4537 - Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Presenter: Lorenza Rimassa
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3521 - Large-scale analysis of CDH1 mutations define a distinctive molecular subset in gastric cancer (GC)
Presenter: Jingyuan Wang
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1484 - Genomic alterations predict clinical response to systemic chemotherapy and immune checkpoint blockade in biliary tract cancer
Presenter: Min Hwan Kim
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study
Presenter: Luis Garcia Rodriguez
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
6574 - Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Presenter: Ahmed Kaseb
Session: Poster Discussion – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1203 - Systemic gut microbial metabolites limit the anti-tumor effect of CTLA-4 blockade in hosts with cancer.
Presenter: Clelia Coutzac
Session: Proffered Paper session - Basic Science
Resources:
Abstract
5510 - Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
Presenter: Robert Charles Doebele
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract